Page last updated: 2024-09-04

docetaxel anhydrous and rtki cpd

docetaxel anhydrous has been researched along with rtki cpd in 2 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (rtki cpd)	Trials (rtki cpd)	Recent Studies (post-2010) (rtki cpd)
12,110	3,216	6,920	744	0	257

Protein Interaction Comparison

Protein	Taxonomy	docetaxel anhydrous (IC50)	rtki cpd (IC50)
Epidermal growth factor receptor	Homo sapiens (human)		0.0584

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE	1
Deng, Z; Du, WW; Fang, L; Jeyapalan, Z; Seth, A; Shan, SW; Yang, BB; Yang, BL; Yee, AJ; Zhang, Y	1

Other Studies

2 other study(ies) available for docetaxel anhydrous and rtki cpd

Article	Year
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. The Prostate, 2009, Jan-01, Volume: 69, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays	2009
Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PloS one, 2011, Volume: 6, Issue:11 Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Green Fluorescent Proteins; Humans; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine; Taxoids; Tyrphostins; Versicans	2011

Article

Year

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

The Prostate, 2009, Jan-01, Volume: 69, Issue:1

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays

2009

Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy.

PloS one, 2011, Volume: 6, Issue:11

Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Green Fluorescent Proteins; Humans; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine; Taxoids; Tyrphostins; Versicans

2011